BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
4.980
-0.250 (-4.78%)
At close: Aug 22, 2025, 4:00 PM
5.00
+0.02 (0.40%)
After-hours: Aug 22, 2025, 7:59 PM EDT
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $120.00K in the quarter ending June 30, 2025, a decrease of -89.13%. This brings the company's revenue in the last twelve months to $868.00K, down -63.88% year-over-year. In the year 2024, BioXcel Therapeutics had annual revenue of $2.27M with 64.20% growth.
Revenue (ttm)
$868.00K
Revenue Growth
-63.88%
P/S Ratio
26.37
Revenue / Employee
$23,459
Employees
37
Market Cap
72.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.27M | 886.00K | 64.20% |
Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
Dec 31, 2022 | 375.00K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BTAI News
- 4 days ago - BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 5 days ago - BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 10 days ago - BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - GlobeNewsWire
- 11 days ago - BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 12 days ago - BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 17 days ago - BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies - GlobeNewsWire
- 22 days ago - BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 4 weeks ago - BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® - GlobeNewsWire